ClinicalTrials.gov
public full text
Public Domain
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserve their bladders and go on active surveillance.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Markers of Response to Intravesical Bladder Cancer Therapy#158217
- Dose Dense MVAC for Muscle Invasive Bladder Cancer#1111623
- Prospective Multicentric Evaluation of a Bladder Preservation Strategy#832464
- Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer#181751
- Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy#465508
Record · ID 1096709
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive